Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026HemaSphereOpen Access

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing

View Full Paper
Ask AI
Bookmark
Share

Authors

NBNatalia BuenacheMLMarta LasaAAAndrés Arroyo

Discussion

Loading...

Member takes

Overview

Randomized trial investigates ctDNA detection for predicting relapse in multiple myeloma, suggesting better monitoring methods.

Key Points

  • This research aims to evaluate a sensitive method for detecting peripheral residual disease (PRD) in multiple myeloma patients.
  • Analyzed longitudinal samples from 84 patients enrolled in PETHEMA/GEM clinical trials.
  • Assessed BM-MRD using EuroFlow-based next-generation flow cytometry (NGF) and PRD using AltumTrackSeq®.
  • Utilized patient-specific multiplexed amplicon mini-panels targeting somatic mutations identified at diagnosis.
  • ctDNA-NGS showed a higher positive predictive value (PPV) of 88.9% compared to 34.5% for BM-MRD by NGF.
  • Specificity improved to 98.4% with ctDNA-NGS versus 70.3% with traditional methods.
  • Detectable ctDNA had a high risk of progression and/or death (HR 11.5; 95% CI 2.66–49.4).

Cite This Study

Buenache et al. (2026) studied this question.

synapsesocial.com/papers/6a362f3bdb0793dc1a536b1ahttps://doi.org/10.1002/hem3.70405
View Full Paper
Ask AI
Bookmark
Share